© 2022 Sollis Therapeutics Inc.
Sollis Therapeutics is a registered trademark of Sollis Therapeutics, Inc.
Design and development by RainCastle Communications
President and Chief Executive
Executive Vice President,
Clinical Research and
President and Chief Executive Officer
Alex DiNello brings over 30 years of experience in the medical industry, including 25 years of experience focusing on the spine and pain markets. He has extensive product, clinical development, and commercialization experience in the space and has brought over 60 products to market across the globe. Prior to joining Sollis Therapeutics, Mr. DiNello served as CTO, COO, and CEO respectively for Relievant Medsystems, Inc. achieving FDA clearance and commercialization for the Intracept System, a novel therapy for the treatment of chronic low back pain. Prior to Relievant, he served as vice president and general manager for Medtronic Kyphon, where he was accountable for $400 million of worldwide business. He was promoted to general manager at Medtronic Kyphon from the position of vice president of research and development. Previously, he was vice president of research and development for Abbott Spine. He has served in various other positions in the medical device industry, including vice president of strategic development and research and development at DePuy Spine, Johnson & Johnson.
Mr. DiNello holds a B.S. in mechanical engineering from University of California at Santa Barbara, an M.E. in biomedical engineering from University of Virginia, and an MBA from Case Western Reserve University.
Executive Vice President, Clinical Research and Operations
Dr. Robert Daly is a seasoned industry veteran with more than 20 years of expertise in the pharmaceutical, biotech and CRO industries. His experience includes leadership roles in clinical operations, clinical research and product development. Prior to joining Sollis, Dr. Daly successfully led many clinical programs nationally and globally in a variety of therapeutic areas, resulting in several product approvals. His experience includes working in both large pharma and small biotech at companies, such as CTI Biopharma, Dupont, SmithKline Beecham, and for a CRO. He has authored more than 30 scientific, peer-reviewed publications and has been a frequent presenter at major medical meetings.
Dr. Daly received his Ph.D. in pharmacology from the Medical College of Pennsylvania, a Master of Science in Molecular Genetics from Drexel University and a Bachelor of Arts degree in biology from Glassboro State College. He also has credentials from the Harvard Business School in Executive Education.